The content is available as a PDF (351.8 KB).
letter . 2021 Jan 27:ciab070. doi: 10.1093/cid/ciab070
The case against delaying SARS-CoV-2 mRNA vaccine boosting doses
Paul Bieniasz
1,2,✉
Paul Bieniasz
1
Laboratory of Retrovirology, The Rockefeller University, New York, NY
2
Howard Hughes Medical Institute, The Rockefeller University, New York, NY
Find articles by Paul Bieniasz
1
Laboratory of Retrovirology, The Rockefeller University, New York, NY
2
Howard Hughes Medical Institute, The Rockefeller University, New York, NY
✉
Corresponding author: Paul Bieniasz , Email: pbieniasz@rockefeller.edu
Received 2021 Jan 21.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
PMCID: PMC7929009 PMID: 33503230
See the article "Accelerate COVID-19 Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines", ciab068.